Investigating the effect of using the GreenNature Deep Lung Support product on the clinical condition of patients with COPD exacerbation

Investigating the effect of using the GreenNature Deep Lung Support product on the clinical condition of patients with COPD exacerbation

The present study is a clinical trial with one control group and two intervention groups, with parallel and double-blind groups, randomized with a sample size of 60 patients. After randomly assigning the patients to three groups, the patients of the first group will receive placebo, the patients of the second group will receive one capsule of deep lung support daily, and the patients of the third group will be given three doses of this supplement daily.Then, on the first day and the day of discharge (ten days later), blood samples will be collected from all patients and clinical symptoms and factors including TNF-a, IL-8, CDC, and CRP will be compared in patients of three groups.

The present study is conducted as a clinical trial on patients with COPD exacerbation referred to Masih Deneshvari Hospital in Tehran. All patients who meet the inclusion criteria will be placed in one of the three study groups after providing full explanations and obtaining written consent.

Inclusion criteria include COPD exacerbation grade D, BMI>18<21 and smoking. Exclusion criteria include the patient's lack of consent to participate in the study, defects in the file, and drug sensitivity.

The patients of the control group will receive placebo, the patients of the first intervention group will be given one capsule of deep lung support daily, and the patients of the second intervention group will be given three doses of this supplement daily.

Borg scale, MMRC, cough, sputum, PH, PCO2, HCO3, lymphocyte, neutrophil, urea, creatinine, AST, ALT, ALP, IL-6, ferritin, D-dimer, LDH T, procalcitonin, TNF-α, IL- 8, CRP, ESR, WBC, RBC

Simple randomization method, individual randomization unit and random number table randomization tool. For randomization, we use a table consisting of random digits from 0 to 9. Each of the figures in this table is repeated the same on average. We start from the first row of the table and move down row by row. For three treatments, we put numbers 1 to 3 for treatment A, numbers 4 to 6 for treatment B, and numbers 7 to 9 for treatment C. We continue the above process until three groups are completed.

In order to prevent any possible complications, the doctor and clinical caregiver are fully aware of the assignment of treatment groups. Participating patients and researchers responsible for data collection and analysis are not aware of the allocation of different study groups.

There is no further information.